Skip to Content

Emergent BioSolutions Inc EBS

Morningstar Rating
$11.20 −0.23 (1.97%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EBS is trading at a 872% premium.
Price
$11.52
Fair Value
$55.76
Uncertainty
Extreme
1-Star Price
$42.79
5-Star Price
$2.51
Economic Moat
Wlq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EBS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$11.43
Day Range
$11.0611.95
52-Week Range
$1.4312.73
Bid/Ask
$11.17 / $11.23
Market Cap
$584.28 Mil
Volume/Avg
2.0 Mil / 5.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.51
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Comparables

Valuation

Metric
EBS
MRK
GILD
Price/Earnings (Normalized)
57.2618.24
Price/Book Value
0.907.805.23
Price/Sales
0.515.153.36
Price/Cash Flow
12.8218.128.62
Price/Earnings
EBS
MRK
GILD

Financial Strength

Metric
EBS
MRK
GILD
Quick Ratio
0.500.680.72
Current Ratio
1.081.251.08
Interest Coverage
−4.923.972.11
Quick Ratio
EBS
MRK
GILD

Profitability

Metric
EBS
MRK
GILD
Return on Assets (Normalized)
−6.85%5.22%8.33%
Return on Equity (Normalized)
−17.48%13.56%24.25%
Return on Invested Capital (Normalized)
−3.92%8.29%12.71%
Return on Assets
EBS
MRK
GILD
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
NmjtgbfyxVvg$81.8 Bil
Merck KGaA ADR
MKKGY
ChqfscxqPlqwh$72.6 Bil
Haleon PLC ADR
HLN
XjftxxgfXjx$40.4 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
JdxftppwBdc$18.2 Bil
Viatris Inc
VTRS
LlblqxtxBltw$14.0 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
SgvnsslxFyyd$13.3 Bil
Catalent Inc
CTLT
McvpflsSlxprw$10.5 Bil
Perrigo Co PLC
PRGO
GnscgqstRkx$3.8 Bil
Prestige Consumer Healthcare Inc
PBH
SrmhrtnmLdyggc$3.6 Bil
Curaleaf Holdings Inc
CURLF
PyhwppxnMqvlr$3.2 Bil

Sponsor Center